IRVINE, Calif., Dec. 16, 2013 /PRNewswire/ -- EP Global Communications, Inc., (OTC Ticker EPGL) makes the following announcement:
In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products.
The Development Agreement was signed last week, being the week of December 8, 2013.
"This is the biggest development for our company in its history," said David T. Markus PhD. "This is just the first of many possible Agreements to come for EPGL and its advanced technologies. EPGL is a leader in BioMEMS technology and the companies we develop with will become leaders as well in this field for their particular products."The two companies have signed a confidentiality agreement due to the sensitive and competitive nature of the technology. Details of the first Development Agreement will remain confidential for now. However, PwC as custodian for AJW Funds Board membership of EPGL has been apprised of the Agreement and its details. EPGL currently has over 15 new advanced technologies and corporations in the medical device and consumer electronics fields have sought to enter relationship with the company. Because of this development, EPGL intends to expand upon and focus on this business model going forward. EPGL Management and Team would like to wish all of our shareholders a Merry Christmas, Happy Hanukkah and Happy New Year. About EP Global Communications, Inc. EP Global Communications, Inc. is an advanced technology development company for both medical devices and consumer electronics. EPGL also holds an FDA 510k cleared medical device called the MPD1. The MPD1 is a revolutionary new diagnostic and therapeutic tool for the muscular originated pain in the human body. Safe Harbor StatementCertain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.